Edwards Lifesciences Corp. Hits New 52-Week High at USD 87.93

Edwards Lifesciences Corp. has reached a significant milestone by hitting a new 52-week high of USD 87.93 on May 26, 2026. This achievement underscores the company's position within the Pharmaceuticals & Biotechnology industry, where it operates as a large-cap entity with a market capitalization of approximately USD 49,952 million. Over the past year, Edwards Lifesciences has recorded a performance increase of 1.67%, contrasting with the S&P 500's robust growth of 29.58%. The company's price-to-earnings (P/E) ratio stands at 34.00, reflecting its valuation in the market. Notably, the stock has a 52-week low of USD 72.30, highlighting the recent upward momentum. Despite a dividend yield of 0.00%, Edwards Lifesciences maintains a low debt-to-equity ratio, indicating a strong balance sheet. The company has demonstrated high management efficiency with a return on equity (ROE) of 15.23%. As it continues to navigate the competitive landscape, this new high marks a pivotal moment in its ongoing performance trajectory.